PERKHIDMATAN INI TIDAK TERSEDIA DI RANTAU ANDA

6 4 G LTD

United Kingdom

Diasas

2015 (11 Tahun)

Diasaskan

Terakhir dalam talian: Tiada aktiviti terkini

Lawati Laman Web

TrustScore tidak tersediaSkor tidak mencukupi untuk memaparkan trend.

Jadilah yang pertama menilai dan mengulas syarikat ini.

SKOR KESELURUHAN

Lesen

--/40

Ulasan

--/60

0 ulasan

Disediakan oleh TrustFinance

TrustScore tidak tersediaSkor tidak mencukupi untuk memaparkan trend.

Jadilah yang pertama menilai dan mengulas syarikat ini.

Dikawal

Disyorkan

XM

(69 ulasan)

Cyprus

2009

(17 tahun)

Maklumat Keselamatan :

CySEC

FSCA

DFSA

Maklumat Keselamatan

Amaran

Syarikat ini pada masa ini Tidak Terbukti.

Sila berwaspada terhadap risiko yang berpotensi!

Lesen

Lesen Gred A

Dikeluarkan oleh pengawal selia yang terkenal di peringkat global, lesen ini memastikan perlindungan pedagang tertinggi melalui pematuhan ketat, pengasingan dana, insurans, dan audit berkala. Penyelesaian pertikaian dan pematuhan kepada piawaian AML/CTF seterusnya meningkatkan keselamatan.

Lesen Gred B

Diberikan oleh pengawal selia serantau yang dihormati, lesen ini menawarkan langkah keselamatan yang mantap seperti pengasingan dana, pelaporan kewangan, dan skim pampasan. Walaupun kurang ketat sedikit berbanding Tahap 1, ia menyediakan perlindungan serantau yang boleh dipercayai.

Lesen Gred C

Dikeluarkan oleh pengawal selia di pasaran baru muncul, lesen ini menawarkan perlindungan asas seperti keperluan modal minimum dan dasar AML. Pengawasan kurang ketat, jadi pedagang harus berhati-hati dan mengesahkan langkah keselamatan.

Lesen Gred D

Daripada bidang kuasa dengan pengawasan minimum, lesen ini seringkali kekurangan perlindungan utama seperti pengasingan dana dan insurans. Walaupun menarik untuk fleksibiliti operasi, ia menimbulkan risiko yang lebih tinggi kepada pedagang.

Maklumat Syarikat

Kenali 6 4 G LTD

Tunjukkan Lagi

Maklumat Syarikat

Kenali 6 4 G LTD

6 4 G LTD, operating under the brand name 64FX, is an online trading provider incorporated in St. Vincent & the Grenadines. The company's mission is to offer a transparent and high-quality trading environment for both retail and institutional clients. It provides access to global financial markets, including Forex, indices, commodities, and shares, utilizing the popular MetaTrader 5 trading platform and offering various account types to suit different trading needs.

Tunjukkan Lagi

Industri

Forex Broker RuncitUTAMA
Kewangan Perkhidmatan Lain

Perisian

Tiada data tersedia

Nampaknya bahagian ini kosong. Kembali semula untuk kemas kini!

Hubungi

Sosial

Syarikat belum mengemas kini maklumatnya.

Ulasan

6 4 G LTD Ulasan

Ulasan

Jumlah 0

Susun

Penapis

Maklumat Syarikat

Kenali 6 4 G LTD

Tunjukkan Lagi

Maklumat Syarikat

Kenali 6 4 G LTD

6 4 G LTD, operating under the brand name 64FX, is an online trading provider incorporated in St. Vincent & the Grenadines. The company's mission is to offer a transparent and high-quality trading environment for both retail and institutional clients. It provides access to global financial markets, including Forex, indices, commodities, and shares, utilizing the popular MetaTrader 5 trading platform and offering various account types to suit different trading needs.

Tunjukkan Lagi

Industri

Forex Broker RuncitUTAMA
Kewangan Perkhidmatan Lain

Perisian

Tiada data tersedia

Nampaknya bahagian ini kosong. Kembali semula untuk kemas kini!

Hubungi

Sosial

Syarikat belum mengemas kini maklumatnya.

Berita

TrustFinance Agensi Perisikan

Tarikh penyelidikan: Mei 14, 2026

The website provides comprehensive resources and tools related to personal finance, including credit cards, banking, loans, insurance, investing, small business, and taxes. Users can compare various financial products, access calculators, and read guides to help make informed financial decisions. The site emphasizes independent and objective information while also featuring partner compensation disclosures.

The website provides comprehensive resources and tools related to personal finance, including credit cards, banking, loans, insurance, investing, small business, and taxes. Users can compare various financial products, access calculators, and read guides to help make informed financial decisions. The site emphasizes independent and objective information while also featuring partner compensation disclosures.

The article discusses GeneAgent, an AI tool designed for gene-set analysis that utilizes large language models (LLMs) to autonomously verify its outputs through interactions with biological databases. It aims to reduce inaccuracies, referred to as 'hallucinations', commonly associated with LLMs. GeneAgent has been evaluated against existing models, showing superior accuracy in generating functional descriptions for gene sets. The study highlights the importance of self-verification in enhancing the reliability of gene function annotations, showcasing GeneAgent's ability to produce informative insights from gene sets derived from various sources, including mouse melanoma cell lines.

The article discusses GeneAgent, an AI tool designed for gene-set analysis that utilizes large language models (LLMs) to autonomously verify its outputs through interactions with biological databases. It aims to reduce inaccuracies, referred to as 'hallucinations', commonly associated with LLMs. GeneAgent has been evaluated against existing models, showing superior accuracy in generating functional descriptions for gene sets. The study highlights the importance of self-verification in enhancing the reliability of gene function annotations, showcasing GeneAgent's ability to produce informative insights from gene sets derived from various sources, including mouse melanoma cell lines.

The article presents the development and validation of an autonomous artificial intelligence (AI) agent designed to assist in clinical decision-making for oncology. This AI agent integrates multimodal data and utilizes advanced tools, including GPT-4, to support personalized treatment strategies. It was evaluated using 20 realistic patient cases, achieving high accuracy in clinical conclusions and effectively citing relevant oncology guidelines. The study illustrates how combining language models with precision oncology tools can enhance decision-making accuracy, paving the way for AI-driven personalized oncology support systems.

The article presents the development and validation of an autonomous artificial intelligence (AI) agent designed to assist in clinical decision-making for oncology. This AI agent integrates multimodal data and utilizes advanced tools, including GPT-4, to support personalized treatment strategies. It was evaluated using 20 realistic patient cases, achieving high accuracy in clinical conclusions and effectively citing relevant oncology guidelines. The study illustrates how combining language models with precision oncology tools can enhance decision-making accuracy, paving the way for AI-driven personalized oncology support systems.

Medicare Supplement Plan G is a high-coverage insurance plan for new Medicare members, covering most out-of-pocket costs not included in Original Medicare, such as copayments and deductibles. It offers comprehensive coverage, including excess charge coverage, but comes with higher premiums. The plan is standardized, meaning all providers offer the same benefits regardless of price. While it does not cover the Part B deductible, it is often considered a valuable option for those willing to pay more for extensive benefits. The best time to enroll is during the six-month open enrollment period starting at age 65 and enrolled in Medicare Part B.

Medicare Supplement Plan G is a high-coverage insurance plan for new Medicare members, covering most out-of-pocket costs not included in Original Medicare, such as copayments and deductibles. It offers comprehensive coverage, including excess charge coverage, but comes with higher premiums. The plan is standardized, meaning all providers offer the same benefits regardless of price. While it does not cover the Part B deductible, it is often considered a valuable option for those willing to pay more for extensive benefits. The best time to enroll is during the six-month open enrollment period starting at age 65 and enrolled in Medicare Part B.

The study investigates zilebesiran, an RNA interference therapeutic agent targeting angiotensinogen, for managing hypertension. In a phase 1 trial, 107 patients received varying doses of zilebesiran or placebo. Results showed significant dose-dependent reductions in serum angiotensinogen levels and sustained decreases in systolic and diastolic blood pressure for up to 24 weeks. Mild injection-site reactions were noted, with no serious adverse events related to hypotension or renal function. The findings support further evaluation of zilebesiran as a potential treatment for hypertension.

The study investigates zilebesiran, an RNA interference therapeutic agent targeting angiotensinogen, for managing hypertension. In a phase 1 trial, 107 patients received varying doses of zilebesiran or placebo. Results showed significant dose-dependent reductions in serum angiotensinogen levels and sustained decreases in systolic and diastolic blood pressure for up to 24 weeks. Mild injection-site reactions were noted, with no serious adverse events related to hypotension or renal function. The findings support further evaluation of zilebesiran as a potential treatment for hypertension.

Disediakan oleh Analisis AI TrustFinance

Berita

TrustFinance Agensi Perisikan

Tarikh penyelidikan: Mei 14, 2026

The website provides comprehensive resources and tools related to personal finance, including credit cards, banking, loans, insurance, investing, small business, and taxes. Users can compare various financial products, access calculators, and read guides to help make informed financial decisions. The site emphasizes independent and objective information while also featuring partner compensation disclosures.

The article discusses GeneAgent, an AI tool designed for gene-set analysis that utilizes large language models (LLMs) to autonomously verify its outputs through interactions with biological databases. It aims to reduce inaccuracies, referred to as 'hallucinations', commonly associated with LLMs. GeneAgent has been evaluated against existing models, showing superior accuracy in generating functional descriptions for gene sets. The study highlights the importance of self-verification in enhancing the reliability of gene function annotations, showcasing GeneAgent's ability to produce informative insights from gene sets derived from various sources, including mouse melanoma cell lines.

The article presents the development and validation of an autonomous artificial intelligence (AI) agent designed to assist in clinical decision-making for oncology. This AI agent integrates multimodal data and utilizes advanced tools, including GPT-4, to support personalized treatment strategies. It was evaluated using 20 realistic patient cases, achieving high accuracy in clinical conclusions and effectively citing relevant oncology guidelines. The study illustrates how combining language models with precision oncology tools can enhance decision-making accuracy, paving the way for AI-driven personalized oncology support systems.

Medicare Supplement Plan G is a high-coverage insurance plan for new Medicare members, covering most out-of-pocket costs not included in Original Medicare, such as copayments and deductibles. It offers comprehensive coverage, including excess charge coverage, but comes with higher premiums. The plan is standardized, meaning all providers offer the same benefits regardless of price. While it does not cover the Part B deductible, it is often considered a valuable option for those willing to pay more for extensive benefits. The best time to enroll is during the six-month open enrollment period starting at age 65 and enrolled in Medicare Part B.

The study investigates zilebesiran, an RNA interference therapeutic agent targeting angiotensinogen, for managing hypertension. In a phase 1 trial, 107 patients received varying doses of zilebesiran or placebo. Results showed significant dose-dependent reductions in serum angiotensinogen levels and sustained decreases in systolic and diastolic blood pressure for up to 24 weeks. Mild injection-site reactions were noted, with no serious adverse events related to hypotension or renal function. The findings support further evaluation of zilebesiran as a potential treatment for hypertension.

Disediakan oleh Analisis AI TrustFinance

6 4 G LTD

XM

Maklumat Syarikat

Maklumat Syarikat